Bucillamine in the treatment of patients with mild to moderate COVID-19: an interview with Michael Frank.

Frank, Michael

Frank, Michael.

Frank M; Revive Therapeutics, Chairman & Chief Executive Officer, Toronto, ON M5C 1P1, Canada.

Future Microbiol ; 17: 157-159, 2022 02.

Article in English | MEDLINE | ID: covidwho-1632374

Subject(s)

Anti-Inflammatory Agents, Non-Steroidal/therapeutic use; COVID-19 Drug Treatment; COVID-19/physiopathology; Cysteine/analogs & derivatives; Drug Repositioning; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage; Anti-Inflammatory Agents, Non-Steroidal/adverse effects; Arthritis, Rheumatoid/drug therapy; COVID-19/diagnosis; COVID-19/pathology; Clinical Trials, Phase III as Topic; Cysteine/administration & dosage; Cysteine/adverse effects; Cysteine/therapeutic use; Drug Industry/organization & administration; Gout/drug therapy; Humans

Keywords

COVID-19; COVID-19 therapeutics; SARS-CoV-2; anti-inflammatory; bucillamine; clinical trial

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Anti-Inflammatory Agents, Non-Steroidal / Cysteine / Drug Repositioning / COVID-19 / COVID-19 Drug Treatment Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: Future Microbiol Journal subject: Microbiology Year: 2022 Document Type: Article Affiliation country: Fmb-2021-0277

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google